功能性大脑网络的广泛的时空模式在阿尔茨海默病的纵向进展中
概括
准周期性模式 (QPPs) 与内在连接网络 (ICNs) 结合,揭示了阿尔茨海默氏病 (AD) 中逐渐发生的大脑网络中断. 这种动态生物标志物框架有助于理解AD的进展和早期检测.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 生物标志物发现发现
背景情况:
- 阿尔茨海默氏症 (AD) 涉及到前面的认知衰退的渐进式功能网络干扰.
- 传统的功能连接分析很难检测过时的网络不稳定性,这对于早期的AD诊断至关重要.
研究的目的:
- 研究准周期性模式 (QPPs) 以确定阿尔茨海默病中与疾病相关的连接性变化.
- 使用静止状态fMRI评估稳定和过渡AD阶段的网络完整性.
- 评估QPP和内在连接网络 (ICN) 作为AD生物标志物的协同作用.
主要方法:
- 利用来自阿尔茨海默病神经成像计划的静止状态fMRI数据.
- 与ICN集成的QPP事件,以评估稳定 (sNC,sMCI,sDAT) 和过渡 (uNC,pMCI) AD队列中的网络完整性.
- 采用克鲁斯卡尔-瓦利斯和恩的统计学意义测试.
主要成果:
- 随着AD的进展,功能连接完整性逐渐下降.
- 在稳定的AD群体中,在皮层下和执行功能网络中发现了早期损伤.
- 在过渡阿尔茨海默症组中观察到视觉和小脑网络的早期中断,QPP发生率下降表明功能断开.
结论:
- QPP和ICN提供了一个动态和敏感的生物标志物框架,用于跟踪阿尔茨海默病的进展.
- 视觉和小脑网络的早期破坏可能成为潜在的早期AD生物标志物.
- 进一步的研究将这种框架与多式成像和临床诊断相结合,可以增强早期AD检测和干预.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764


